Cohera Medical, Inc.®, a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.
TissuGlu is an internal surgical adhesive for large flap surgeries, such as
abdominoplasties, that helps reduce fluid accumulation and the need for postsurgical
drains. Its unique chemical composition is resorbable, non-toxic, forms a strong bond
between tissue layers and allows for natural healing, which ultimately may provide the
patient with a quicker return to normal activity.
Currently, most patients who undergo abdominoplasty procedures require the insertion
of drains to remove fluids that accumulate under the skin at the surgical site. In some
cases, drainage is inadequate, and the excess fluid accumulation (seroma) often
requires additional procedures for removal. TissuGlu adheres the tissue flap to the
underlying tissue (which is created during the procedure) to reduce fluid that can
accumulate in the space and ultimately reduce the time to drain removal. With the use
of TissuGlu, patients may have drains removed faster, which may lead to a more
comfortable recovery and a quicker return to normal activity.
TissuGlu will be commercially available in Germany in the third quarter of 2011. Cohera
Medical is also actively pursuing U.S. FDA approval.
For more information and to view an animation of how TissuGlu Surgical Adhesive works, visit www.coheramedical.com/products.